Blair William & CO Avadel Pharmaceuticals PLC Transaction History

Blair William & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 13, 2021	SELL	$6.61 - $10.07 $67,752 - $103,217	-10,250 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$5.03 - $7.95 $1,257 - $1,987	250 Added 2.5%	10,250 $68,000
Q3 2020 Nov 06, 2020	SELL	$5.02 - $8.98 $12,549 - $22,450	-2,500 Reduced 20.0%	10,000 $50,000
Q2 2020 Aug 12, 2020	SELL	$7.25 - $11.75 $32,625 - $52,875	-4,500 Reduced 26.47%	12,500 $101,000
Q1 2020 May 11, 2020	BUY	$4.06 - $10.64 $69,020 - $180,880	17,000 New	17,000 $135,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $626M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.